Global survey finds one in four type 2 diabetes patients do not take basal insulin as prescribed
12 June 2012 | By
One in four people with type 2 diabetes did not dose their long-acting (basal) insulin correctly...
List view / Grid view
News
Lilly expands strategic partnership with Novast to serve chinese patients with high-quality branded generic medicines
12 June 2012 | By Eli Lilly and Company
Lilly will increase equity position in Novast by $20 million...
Amgen completes acquisition of Mustafa Nevzat Pharmaceuticals
12 June 2012 | By Amgen
Amgen announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals...
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
12 June 2012 | By Sanofi
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare...
New epidemiological data provide additional safety evidence for Lantus®
11 June 2012 | By Sanofi
New results of a large-scale epidemiological program announced...
Stiefel signs worldwide acquisition and license agreement for Toctino®
11 June 2012 | By GlaxoSmithKline
Stiefel has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd...
Catalent expert conducts workshop on Solid Dosage Forms
11 June 2012 | By Catalent Pharma Solutions
Michael Valazza, to conduct a workshop on “Coordination of Activities and Responsibilities for Solid Dosage Forms”...
Daiichi Sankyo launches antihypertensive agent olmesartan in Mexico
11 June 2012 | By Daiichi Sankyo
Daiichi Sankyo Group’s leading antihypertensive franchise olmesartan medoxomil launched...
Sanofi submits application for regulatory approval for Lyxumia®
11 June 2012 | By Sanofi
Sanofi announced that the marketing authorization application for Lyxumia®...
A new study with ‘real world’ data shows greater efficacy of Victoza(R)
11 June 2012 | By Novo Nordisk
New data show that Victoza® provided greater reductions in HbA1c...
Lilly and Incyte’s oral JAK1 and JAK2 inhibitor, Baricitinib, showed positive results in Phase IIb study
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
11 June 2012 | By Novartis
New long-term data for Gilenya®...
Lilly and Boehringer Ingelheim present data at the 72nd American Diabetes Association Scientific Sessions® from Phase II studies comparing investigational novel basal insulin to insulin glargine
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
9 June 2012 | By GlaxoSmithKline
Detailed 52 and 32-week data from the first two Phase III studies...
